Background: Due to its use of ionising radiation, the field of nuclear medicine is a unique and significant part of medical diagnostics and patient treatment. The aim of this study was to assess the internal exposure of nuclear medicine employees to radioiodine 131I and technetium 99mTc as well as to assess the external exposure doses. Material and Methods: The radioiodine 131I and technetiu...

BACKGROUND The Cooperative Thyrotoxicosis Therapy Follow-up Study reported cancer mortality after use of radio-iodine (131I), surgery, and other treatments in patients with hyperthyroidism, started during 1946-1964 and followed through 1968. In 1984, the National Cancer Institute initiated a continued follow-up (FU) of the same cohort through 1990, to assess potential carcinogenic effects of 13...

Progress in the use of monoclonal antibodies (MAbs) for the treatment of solid tumors is limited by a number of factors, including poor penetration of the labeled IgG molecule into the tumors, their inability to reach the tumor in sufficient quantities without significant normal tissue toxicity, and the development of a human antimouse antibody response to the injected MAb. One possible way to ...

Neuroblastoma is a pediatric malignancy with a poor prognosis at least partly attributable to an early pattern of dissemination. New approaches to treatment of micrometastases include targeted radiotherapy using radiolabeled antibodies or molecules which are taken up preferentially by tumor cells. Multicellular tumor spheroids (MTS) resemble micrometastases during the avascular phase of their d...

131I treatment is an important management method for patients with differentiated thyroid cancer (DTC). Unsuccessful 131I ablation drastically affects the prognosis of the patients. This study aimed to analyze potential predictive factors influencing the achievement of a disease-free status following the first 131I therapy. This retrospective review included 315 DTC patients, and multiple facto...

Purpose: The survival for children with relapsed or metastatic neuroblastoma remains poor. More effective regimens with acceptable toxicity are required to improve prognosis. Iodine-131–metaiodobenzylguanidine (131I-MIBG) selectively targets radiation to catecholamine-producing cells, including neuroblastoma cells. A pilot study was performed to examine the feasibility of a novel regimen combin...

PURPOSE A study was designed to define the therapeutic efficacy, safety, and toxicity of two sequential high-dose treatments of radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell carcinoma. Here, we report the dosimetric analysis and the relationship between the development of a human antichimeric antibody response and altered pharmacokinetics. EXPERIMENTAL DESIGN Pa...

UNLABELLED The goal of this study was to reduce the salivary symptoms of pain and xerostomia caused by 131I therapy for papillary and follicular thyroid carcinoma. METHODS In a single-blind controlled prospective study of 60 patients, we investigated whether pilocarpine, 5 mg orally every 8 h for 1 wk after 131I therapy, would reduce salivary symptoms. All patients received 8 mg of dexamethas...

objective(s): we investigated a frequency of lower extremity uptake on the radioactive iodine (rai) whole body scan (wbs) after rai treatment in patients with differentiated thyroid cancer, in order to retrospectively examine whether or not the frequency was pathological. methods: this retrospective study included 170 patients with thyroid cancer, undergoing rai treatment. overall, 99r (58%) an...

background:  the aim of the study was to estimate the radiation dose during emergency exposure to patients treated with iodine-131 during the isolation period. materials and methods: the dose rate from a sample of 192 patients administrated by three different radioactivity of 131i (3.7, 5.55 and 7.4 gbq) was measured, at 1 meter after 1, 24 and 48 hours post dose administration, at three differ...